CLONIDINE patch labels and packages: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Pratik Bahekar (talk | contribs)
nocaptcha
3,696 edits
Created page with "__NOTOC__ {{Clonidine}} {{CMG}}; {{AE}} {{PB}} '''''For patient information, click here'''''. ==Labels and Packages== <ref name="dailym..."
 
Pratik Bahekar (talk | contribs)
nocaptcha
3,696 edits
 
Line 7: Line 7:
==Labels and Packages==
==Labels and Packages==


{|
|-
|[[Image:Clonidine10.PNG|thumb|800px]]
|-
|}


PRINCIPAL DISPLAY PANEL - 0.2 mg/day
Contents:
4 Systems and
4 Adhesive Covers
NDC 0378-0872-99
Rx only
Clonidine
Transdermal System, USP
0.2 mg/day
Programmed delivery in vivo of 0.2 mg
clonidine per day for one week.
Each system contains 5.04 mg of
clonidine. The inactive components
are mineral oil, polyisobutylene,
colloidal silicon dioxide, pigmented
polyethylene/polyester film, and
silicone/polyester film.
FOR TRANSDERMAL USE ONLY.
Keep this and all drugs
out of the reach of children.
See package insert for dosage information.
Store at 20° to 25°C (68° to 77°F). [See
USP Controlled Room Temperature.]
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
Mylan.com
M0872-99-4C:R10
{|
|-
|[[Image:Clonidine11.PNG|thumb|800px]]
|-
|}
PRINCIPAL DISPLAY PANEL - 0.3 mg/day
Contents:
4 Systems and
4 Adhesive Covers
NDC 0378-0873-99
Rx only
Clonidine
Transdermal System, USP
0.3 mg/day
Programmed delivery in vivo of 0.3 mg
clonidine per day for one week.
Each system contains 7.56 mg of
clonidine. The inactive components
are mineral oil, polyisobutylene,
colloidal silicon dioxide, pigmented
polyethylene/polyester film, and
silicone/polyester film.
FOR TRANSDERMAL USE ONLY.
Keep this and all drugs
out of the reach of children.
See package insert for dosage information.
Store at 20° to 25°C (68° to 77°F). [See
USP Controlled Room Temperature.]
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
Mylan.com
M0873-99-4C:R10
{|
|-
|[[Image:Clonidine11.PNG|thumb|800px]]
|-
|}
<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = CLONIDINE PATCH [MYLAN PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7adfc439-e6d0-4593-87dd-0eef36d33c6d | publisher =  | date =  | accessdate = 5 February 2014 }}</ref>
<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = CLONIDINE PATCH [MYLAN PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7adfc439-e6d0-4593-87dd-0eef36d33c6d | publisher =  | date =  | accessdate = 5 February 2014 }}</ref>


==References==
==References==

Latest revision as of 04:54, 6 February 2014

Clonidine
CATAPRES® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
CLONIDINE patch ® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
DURACLON (clonidine hydrochloride) injection® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Clonidine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

For patient information, click here.

Labels and Packages


PRINCIPAL DISPLAY PANEL - 0.2 mg/day

Contents: 4 Systems and 4 Adhesive Covers

NDC 0378-0872-99

Rx only

Clonidine Transdermal System, USP

0.2 mg/day

Programmed delivery in vivo of 0.2 mg clonidine per day for one week.

Each system contains 5.04 mg of clonidine. The inactive components are mineral oil, polyisobutylene, colloidal silicon dioxide, pigmented polyethylene/polyester film, and silicone/polyester film.

FOR TRANSDERMAL USE ONLY.

Keep this and all drugs out of the reach of children.

See package insert for dosage information.

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Mylan.com

M0872-99-4C:R10

PRINCIPAL DISPLAY PANEL - 0.3 mg/day

Contents: 4 Systems and 4 Adhesive Covers

NDC 0378-0873-99

Rx only

Clonidine Transdermal System, USP

0.3 mg/day

Programmed delivery in vivo of 0.3 mg clonidine per day for one week.

Each system contains 7.56 mg of clonidine. The inactive components are mineral oil, polyisobutylene, colloidal silicon dioxide, pigmented polyethylene/polyester film, and silicone/polyester film.

FOR TRANSDERMAL USE ONLY.

Keep this and all drugs out of the reach of children.

See package insert for dosage information.

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Mylan.com

M0873-99-4C:R10

[1]

References

  1. ↑ "CLONIDINE PATCH [MYLAN PHARMACEUTICALS INC.]". Retrieved 5 February 2014.

Template:Antimigraine preparations

Retrieved from "https://www.wikidoc.org/index.php?title=CLONIDINE_patch_labels_and_packages&oldid=939167"